Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers
Our study reports the first CD28 bsAb targeting Nectin-4 and highlights the potential of CD28 × Nectin-4 bsAbs as a new immunotherapeutic modality. The findings support the clinical development of RNDO-564 in patients with locally advanced and metastatic UC and other Nectin-4 positive malignancies.
Authors
- Manpreet Kaur (ORCID: https://orcid.org/0000-0003-3069-1562)
- Shelley Force Aldred (ORCID: https://orcid.org/0000-0003-2095-7646)
- Ruth Chu
- Laura Davison
- Elaine C Chen
- Udaya S. Rangaswamy (ORCID: https://orcid.org/0000-0002-3994-3861)
- Soumili Chattopadhyay
- Stephanie Arteaga (ORCID: https://orcid.org/0000-0002-7064-1642)
- Mathias Rickert (ORCID: https://orcid.org/0000-0003-4034-9090)
- Katja Rüger
- Starlynn Clarke
- Katherine E. Harris (ORCID: https://orcid.org/0000-0001-8778-9144)
- Nathan D. Trinklein
- Ian E. Smith
Institutions
- Rodin Therapeutics (United States) (US)
- Chrono Therapeutics (United States) (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-011323
- Citations
- 4
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 3.19